- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Rivaroxaban – March 2020
Rivaroxaban: Tablet 2.5 mg; Xarelto®
Last updated
17 July 2020